• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

UAE’s G42 Healthcare signs MoU to Collaborate with Israel’s NanoScent

Share:

August 26, 2020

The Abu Dhabi-based company is reportedly in talks to co-develop a COVID-19 test that can detect positive cases of the coronavirus from exhaled nasal air.

Abu Dhabi’s G42 Healthcare has signed a preliminary agreement with Israel’s NanoScent to develop, distribute, and manufacture a COVID-19 test that can detect positive cases of the coronavirus from exhaled nasal air, the UAE state news agency WAM has reported.

Named Scent Check, the device works by reportedly detecting “a combination of volatile organic compounds – or ‘VOC Signature’,” from exhaled nasal air that comes from the host response to the SARS-CoV-2 infection. Captured through an “air trap”, Scent Check features a small bag fitted with a straw in which the subject blows nasal air. The result can apparently be provided within 30 to 60 seconds.

WHY IT MATTERS

According to the announcement, the “non-invasiveness and the rapidity of results give Scent Check the potential to transform the diagnostics industry globally.” Other advantages cited include the ability to test in small and large settings, as well as the test being affordable.

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

This latest memorandum of understanding (MoU) is amongst a series of deals between the UAE and Israel to tackle the pandemic, revealed during a statement announcing a normalising of diplomatic relations.

G42 Healthcare is currently spearheading the world’s first Phase III trials of a COVID-19 vaccine, following the apparent success of Phase I and Phase II trials conducted by China’s Sinopharm.

ON THE RECORD

“We are at the forefront of the battle against COVID-19 and committed to developing impactful innovative programmes and solutions to improve and safeguard public health,” said Ashish Koshy, CEO of G42 Healthcare. “Through this collaboration with NanoScent, we will be adding another powerful solution to our comprehensive diagnostics portfolio, which already includes PCR and LamPORE testing.

“This partnership also reaffirms the need to tackle the COVID-19 pandemic through a joint global effort in which best-in-breed organisations share their expertise and technologies for the benefit of society.”

Source: Mobihealth News

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • Monroe Capital Supports Vivo Capital LLC’s Acquisition of Serán Bioscience, Inc.Monroe Capital Supports Vivo Capital LLC’s Acquisition of Serán Bioscience, Inc.
  • Indegene Acquires DT Associates, Provides End-To-End Enterprise Solution For Customer Excellence – From Consulting To OperationsIndegene Acquires DT Associates, Provides End-To-End Enterprise Solution For Customer Excellence – From Consulting To Operations
  • Contract Manufacturing Organization Market to Hit USD 188.07 Billion with 9.4% CAGR by 2026Contract Manufacturing Organization Market to Hit USD 188.07 Billion with 9.4% CAGR by 2026
  • Report: Digital Health Tools Fail to Keep Up with Patients’ ExpectationsReport: Digital Health Tools Fail to Keep Up with Patients’ Expectations
  • Merck to Acquire ThemisMerck to Acquire Themis
  • Contributed: Discipline During a Gold Rush? Yes, Now More Than Ever When Healthcare Data is InvolvedContributed: Discipline During a Gold Rush? Yes, Now More Than Ever When Healthcare Data is Involved
  • JMD Properties, Inc. Acquires Diagnostic Oncology Company, Changes Focus to BiotechJMD Properties, Inc. Acquires Diagnostic Oncology Company, Changes Focus to Biotech
  • Fate Therapeutics Strikes Multi-Billion Dollar Cell Therapy Deal with JanssenFate Therapeutics Strikes Multi-Billion Dollar Cell Therapy Deal with Janssen

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications